A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...

(a) Schematic of IHoM and IHeM models. NC: neutral cells; AC: cells carrying antigen mutations; IC: immune-recognizable cells; EC: immune-escaped cells. (b) Response of IHoM and IHeM to monotherapies ...

Targeted cancer therapies are an expanding field of effective therapeutic approaches. While previous chemotherapy agents indiscriminately killed rapidly proliferating cells, newer “precision medicine” ...

Efficacy and safety of regorafenib combined with immune checkpoint inhibitors in advanced hepatocellular carcinoma patients progressing after lenvatinib treatment. This is an ASCO Meeting Abstract ...